Loading
A phase 1/2 trial of fruquintinib and pembrolizumab in colorectal cancer, run by National Cancer Center Hospital East, not yet recruiting.
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer is a phase 1/2, interventional study registered as NCT07591597 by National Cancer Center Hospital East, with a registry enrolment figure of 68 participants, started 2026-05 and due to reach its primary completion in 2027-07. Interventions recorded: S-531011; Fruquintinib; Pembrolizumab. Conditions listed: Metastatic Colorectal Neoplasms; Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer. Primary outcome: Dose-Limiting Toxicity (DLT) Rate [Phase Ib Part]; Objective Response Rate (ORR) [Phase II Part]. Colorectal eligibility wording from the registry: "Patients with histologically confirmed unresectable adenocarcinoma of the colon or rectum". No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Mismatch-repair deficient (MSI-high) colorectal cancer, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.